Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney composite outcome median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney failure median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to higher diabetic ketoacidosis median compared with placebo (moderate certainty).
Bupropion leads to higher smoking cessation (at least six months of compared with placebo/no pharmacological treatment (high certainty).
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
Bupropion leads to higher dropouts due to treatment compared with placebo/no pharmacological treatment (high certainty).
Antibiotics showed no clear difference in pain ‐ pain at 24 hours compared with placebo (high certainty).
Antibiotics leads to lower pain ‐ pain at 2 to 3 days compared with placebo (high certainty).
Antibiotics showed no clear difference in pain ‐ pain at 4 to 7 days compared with placebo (high certainty).
Antibiotics probably leads to lower pain ‐ pain at 10 to 12 days compared with placebo (moderate certainty).
Antibiotics leads to higher vomiting, diarrhoea or rash compared with placebo (high certainty).
Antibiotics leads to lower abnormal tympanometry ‐ 2 to 4 weeks compared with placebo (high certainty).
Antibiotics showed no clear difference in abnormal tympanometry ‐ 3 months compared with placebo (high certainty).
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to geographic atrophy compared with placebo (low certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
It is very uncertain whether lutein with or without zeaxanthin changes adverse effects compared with placebo (very low certainty).